

25 **Abstract**

26 **Background:** SARS-CoV-2 is found in conjunctival swabs and tears of COVID-19 patients.
27 However, the presence of SARS-CoV-2 has not been detected in the human eye to date. We
28 undertook this study to analyze the prevalence of SARS-CoV-2 in human post-mortem ocular
29 tissues.

30 **Methods:** The expression of SARS-CoV-2 RNA was assessed by RT-PCR in corneal and scleral
31 tissues from 33 surgical-intended donors who were eliminated from a surgical use per Eye Bank
32 Association of America (EBAA) donor screening guidelines or medical director review or positive
33 COVID-19 test. Ocular levels of SARS-CoV-2 RNA (RT-PCR), Envelope and Spike proteins
34 (immunohistochemistry) and anti-SARS-CoV-2 IgG and IgM antibodies (ELISA) in blood were
35 evaluated in 10 COVID-19 donors.

36 **Findings:** Of 132 ocular tissues from 33 surgical-intended donors, the positivity rate for SARS-
37 CoV-2 RNA was ~13% (17/132). Of 10 COVID-19 donors, six had PCR positive post-mortem
38 nasopharyngeal swabs whereas eight exhibited positive post-mortem anti-SARS-CoV-2 IgG
39 levels. Among 20 eyes recovered from 10 COVID-19 donors: three conjunctival, one anterior
40 corneal, five posterior corneal, and three vitreous swabs tested positive for SARS-CoV-2 RNA.
41 SARS-CoV-2 spike and envelope proteins were detected in epithelial layer of the corneas that were
42 procured without Povidone-Iodine (PVP-I) disinfection.

43 **Interpretations:** Our study showed a small but noteworthy prevalence of SARS-CoV-2 in ocular
44 tissues from COVID-19 donors. These findings underscore the criticality of donor screening
45 guidelines, post-mortem nasopharyngeal PCR testing and PVP-I disinfection protocol to eliminate
46 any tissue harboring SARS-CoV-2 being used for corneal transplantation.

47 **Funding:** Research grant from EBAA and National Institutes of Health.

48 **Introduction:**

49 The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus
50 -2 (SARS-CoV-2) has been the current focus of research as it has significantly disrupted many
51 livelihoods. The SARS-CoV-2 virus is highly infectious and transmitted primarily through
52 respiratory droplets and upon contact with infected persons. Studies to date have suggested that
53 COVID-19 patients have a high viral load in the upper respiratory tract at disease onset [1, 2].
54 There is a strong possibility the virus may contaminate the ocular surface via respiratory droplets
55 after coughing, sneezing, and hand-to-eye contact. In January 2020, an ophthalmologist contracted
56 COVID-19 from an asymptomatic glaucoma patient; the initial indication was that the ocular
57 surface served as a mediator of viral infection [3]. Studies have shown that SARS-CoV-2 may
58 cause conjunctivitis, and viral RNA has been detected in tears and retinal biopsies of COVID-19
59 patients [4-11]. Conjunctival manifestations have been reported at rates as low as 0.8% [6] in the
60 largest retrospective study from China, and at rates of 6% [9], 32% [5], and as high as 66% [10]
61 in other studies. These reports indicate that the ocular surface may act as a possible mode of disease
62 transmission.

63 SARS-CoV-2 relies on angiotensin-converting enzyme-2 (ACE-2) as its receptor on
64 human cells, along with TMPRSS2 or Furin protease for viral entry into host cells. Ocular surface
65 cells of the cornea and conjunctiva epithelial cells have been shown to express ACE-2 and
66 TMPRSS2 [12, 13]. Hence, based on the recent evidence, potential SARS-CoV-2 transmission
67 through the ocular surface remains a significant concern. The route of transmission and infiltration
68 of the virus within the ocular tissue is still unknown. Answering these questions are of critical
69 importance concern to ophthalmologists, eye banking industry, and the field of sight-restoring
70 transplantation.

71 Although it is believed that SARS-CoV-2 primarily transmits via respiratory droplets,
72 extra-respiratory transmission via blood is theoretically possible because studies have shown the
73 presence of SARS-CoV-2 RNA in blood samples [14, 15]. Hence, there is a strong possibility that
74 various ocular tissues feature different degrees of transmission risk. While few recent studies and
75 case reports have detected viral RNA in tears and conjunctival swabs, the presence of SARS-CoV-
76 2 has not been shown within ocular tissues of COVID-19 patients. This study was designed to
77 systematically evaluate the presence of SARS-CoV-2 RNA and proteins in post-mortem ocular
78 tissues of COVID-19 positive donors.

79

80 **Material and Methods:**

81 This study was performed in compliance with the Declaration of Helsinki and Eye Bank
82 Association of America (EBAA) and Food and Drug Administration (FDA) regulations. Consent
83 for research was obtained prior to procurement from each donor family. The University of
84 Michigan medical school institutional review board (IRBMED) determined that this study does
85 not fit the definition of human subjects research requiring IRB approval. Laboratory experiments
86 from this study were approved by the Institutional Biosafety Committee (IBC) at the Wayne State
87 University (IBC# 20-04-2164). A simplified outline of this study is provided in Fig. 1 and detailed
88 procedures are described below.

89 *Donor screening criteria and procurement procedure*

90 Donor enrollment criteria included a positive COVID-19 PCR test within 15 days of death. All 10
91 donors had active COVID-19 at the time of death and were reported to state agencies as COVID-
92 19 deaths. The donors' families had provided consent for cornea and whole eye recovery for
93 research purposes, and all cases were in the U.S. states of Michigan or New Jersey. Appropriate

94 personal protective equipment (PPE) and standard disposable instruments were used for eye
95 recovery purposes. A postmortem nasopharyngeal (NP) swab and blood were collected for
96 serological analysis. The left eye was recovered first, followed by the right eye, with disinfection
97 of the instrument taking place between the recovery of each eye. The ocular tissue was
98 swabbed starting with the left eye. The left eye was opened, and the anterior surface was soaked
99 in 5% povidone-iodine (PVP-I) (Aplicare, Meriden, CT) for five minutes. The eye
100 was thoroughly flushed with sterile eyewash solution (Medique Products, Fort Myers, FL). The
101 lid speculum was carefully inserted, followed by a conjunctival swab collection, and the tissue was
102 excised 360°. A sample of the conjunctival tissue was placed in a 5mL microcentrifuge tube
103 (Eppendorf AG, Hamburg, Germany) containing 4% paraformaldehyde (PFA). The remaining
104 tissue was soaked in PVP-I for another five minutes, followed by a sterile saline flush. A swab of
105 the anterior cornea was taken by touching the swab to the cornea's epithelial surface (referred to
106 as anterior cornea). Next, the whole eye was enucleated and positioned in the RE-One chamber
107 (RE-One Sagl, Lugano, Switzerland, acquired via Medical Innovation Partners International,
108 Dallas, TX) for corneal excision. The cornea was removed and thereafter swabbed on the cornea's
109 endothelial surface (referred to as posterior cornea). The cornea was stored in a container with 4%
110 PFA. The iris and lens were carefully removed, and the iris stored without storage media at -80
111 °C. The vitreous was swabbed as well. The RE-One chamber was assembled, and
112 the posterior part was submerged in a fixative solution. The instruments were disinfected
113 using CaviWipes™ (Metrex, Orange, CA). The tissue recovery for each donor resulted in nine
114 swabs for SARS-CoV-2 PCR testing (one NP, two conjunctiva, two anterior corneas, two posterior
115 corneas, and two vitreous) and a postmortem blood sample for measuring anti-SARS-CoV-2 IgM

116 and IgG using ELISA. The nine swabs and blood samples were immediately shipped to Eurofins
117 VRL Laboratories (Centennial, CO USA) for SARS-CoV-2 testing by qRT-PCR.

118 *Diagnostic testing*

119 RT-PCR testing was performed using The BioGX SARS-CoV-2 Reagents for BD MAX™ System
120 at Eurofins VRL Laboratories. The U.S. Food and Drug Administration (FDA) granted Emergency
121 Use Authorization (EUA) for The BioGX SARS-CoV-2 Reagents for BD MAX™ System on
122 April 3, 2020. All tests were performed after that date. The BD SARS-CoV-2 Reagents for BD
123 MAX System utilized multiplexed primers and probes targeting RNA from the nucleocapsid
124 phosphoprotein gene (N1 and N2 regions) of the SARS-CoV-2 coronavirus, and the human RNase
125 P gene was used as an internal control. To eliminate false positives, if the Ct value (number of
126 cycles) was higher than 37, samples were deemed positive only if both N1 and N2 Cts were
127 detectable with positive amplification. Otherwise, samples were deemed negative/undetectable.
128 Serological testing for SARS-CoV-2 was performed using the EUROIMMUN Anti-SARS-CoV-
129 2 IgG ELISA kit (Mountain Lakes, NJ USA) and the Gold Standard Diagnostics SARS-CoV-2
130 IgM ELISA Test Kit (Davis, CA USA) according to manufacturer's instructions.

131 *RT-PCR detection for SARS-CoV-2 in ocular tissues*

132 To assess the presence of SARS-CoV-2 in ocular tissue, we evaluated tissues that were procured
133 for surgical purposes but later ruled out due to positive post-mortem tests or signs/symptoms of
134 COVID-19. Corneal (n =66) and scleral (n = 66) tissue from 33 different donors were dissociated
135 using the bead lysis method followed by total RNA extraction using Trizol reagent (Invitrogen,
136 Carlsbad, CA) per the manufacturer's instructions. cDNA was prepared using 1 mg of RNA using
137 a Maxima first-strand cDNA synthesis kit (Thermo Scientific, Waltham, MA) per the
138 manufacturer's instructions. Viral RNA was detected in the cDNA using SARS-CoV-2

139 nucleoprotein gene-specific Taqman probe primers purchased from Integrated DNA Technologies
140 (Coralville, IA). The primer sequence used in the assay was adopted from the Chinese Center for
141 Disease Control and Prevention primers for detection of 2019-nCoV: Forward primer:
142 GGGGAAGTTCTCCTGCTAGAAT; Reverse primer: CAGACATTTTGCTCTCAAGCTG;
143 Fluorescent probe: 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. RT-PCR was
144 conducted using the StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA).
145 The quantification of gene expression was determined by the Standard Quantification method and
146 expressed as Ct values. Tissue samples with Ct value ≤ 37 were considered positive, while
147 undetermined Ct values and Ct values >37 were considered negative. The whole-genome SARS-
148 CoV-2 RNA was used as a positive control, while a no-template mixture was used as a negative
149 control for the assay.

150 *Immunohistochemistry*

151 Fixed corneas were passed through a series of sucrose gradient (10%, 20%, 30%), and embedded
152 in OCT (Tissue-Tek[®]-Sakura, Torrance, CA). Ten-micrometer thin sections were prepared using
153 a cryotome (HM525 NX, ThermoFisher Scientific, Waltham, MA) and mounted onto lysine-
154 coated glass slides (Fisherbrand, Thermo Scientific, Waltham, MA). The sections were
155 permeabilized and blocked with 10% normal goat serum with 0.5% Triton X-100 for two hours at
156 RT and incubated overnight with primary mouse anti-SARS-CoV-2 spike or envelope antibodies
157 (BEI Resources, NIAID) (1:100). The next day, sections were rinsed four times with PBS
158 (10 minutes each) and incubated with anti-mouse/rabbit Alexa Fluor 485/594-conjugated
159 secondary antibodies (1:200) for 2 h at RT. The sections were extensively rinsed with PBS (four
160 washes, 10 minutes each) and the slides were mounted in Vectashield anti-fade mounting medium

161 (Vector Laboratories, Burlingame, CA) and visualized using a Keyence microscope (Keyence,
162 Itasca, IL) at different magnifications.

163

164 **Results:**

165 **PCR testing on surgical rule-out tissues**

166 To detect the presence of SARS-CoV-2 RNA, we isolated RNA from the sclera and cornea
167 (without separating different layers) of asymptomatic positive donors and donors that had
168 symptoms of COVID-19 without positive COVID-19 PCR test. All of these donors were classified
169 in one of three different groups, and their testing results are summarized in Table 1. Group 1
170 primarily consisted of eye-only donors who had passed EBAA screening criteria with donors that
171 were deemed appropriate for surgical use. We performed NP swab at the time of corneal recovery
172 and received a positive test result. Group 2 primarily consisted of donors early in the pandemic
173 when testing was not widespread. Corneas were ruled out for surgical use after consultation with
174 medical directors or following the application of EBAA donor eligibility guidelines based on signs
175 and symptoms. The majority of these cases had a negative COVID-19 PCR test. Group 3 consisted
176 of donors who neither had signs or symptoms nor tested positive for COVID-19 but had spent a
177 significant amount of time with someone with COVID-19. Results from SARS-CoV-2 RT-PCR
178 testing are summarized in Table 1. The highest positivity rate of 17% for sclera and 11% for cornea
179 was observed in Group 1. In Group 2, 12% of scleral samples and 15% of corneal samples were
180 positive for SARS-CoV-2 viral RNA. None of the tissues from the two donors in Group 3, who
181 had close contact with a COVID-19 patient, showed any detectable level of SARS-CoV-2 RNA.

182 **Detecting SARS-CoV-2 in donors that died due to COVID-19**

183 After observing 13% (17 out of 132) SARS-CoV-2 RNA prevalence rate in surgical rule-out
184 tissues, our next goal was to systematically evaluate the presence of SARS-CoV-2 in different
185 ocular layers of research consented donors that died due to COVID-19. We analyzed ocular swabs
186 from 10 different donors with a median age of 66 (range 46-90). Donor demographics and pre-
187 mortem testing results are provided in Table 2. Detailed case summaries with a timeline of disease
188 progression and testing results are provided below. The testing results are also summarized in
189 Table 3.

190 *Case Summaries*

191 **Case #1:** A Caucasian male in his 60s was admitted for potentially infected lower extremity ulcers
192 and type I diabetes mellitus (DM). On the same day, the patient tested positive for COVID-19 by
193 PCR. Follow-up positive COVID-19 PCR tests were reported 13 and 28 days after hospital
194 admission. The patient passed away six days after last positive COVID-19 test. Post-mortem NP
195 swab test was positive for SARS-CoV-2 RNA along with the presence of anti-SARS-CoV-2 IgG-
196 Ab. Among the ocular tissue swabs, the right posterior cornea tested positive for SARS-CoV-2
197 RNA. All other ocular tissue swabs were negative.

198 **Case #2:** A Caucasian female in her late 80s was presented to an emergency room (ER) with fever,
199 worsening cough, shortness of breath, body aches, and poor oral intake. On the same day, the
200 patient tested positive for COVID-19 via PCR assay. The patient subsequently passed away nine
201 days after testing positive for COVID-19. The post-mortem NP swab test was positive for SARS-
202 CoV-2 RNA while the anti-SARS-CoV-2 IgG Ab test was negative. Among the ocular tissue
203 swabs, the left posterior cornea tested positive for SARS-CoV-2 RNA. All other ocular tissue
204 swabs were negative.

205 **Case #3:** A Caucasian male in his early 70s was admitted to the hospital with symptoms of
206 respiratory distress. On the same day, the patient was tested positive for COVID-19 via PCR
207 assay. The patient passed away seven days after hospital admission and testing positive for
208 COVID-19. Surprisingly, the post-mortem NP swab test was negative for SARS-CoV-2 RNA.
209 However, the anti-SARS-CoV-2 IgG-Ab test was positive indicating that this donor might have
210 had SARS-CoV-2 infection well before admission to the hospital. All ocular tissue swabs were
211 negative.

212 **Case #4:** A South Asian male in his 60s was admitted to the hospital with
213 right middle cerebral artery stroke. The patient tested positive for COVID-19 via PCR assay after
214 two months of hospital stay. The patient subsequently passed away 15 days after testing positive
215 for COVID-19. Similar to case #3, the post-mortem NP swab test was negative for SARS-CoV-2
216 RNA. However, the anti-SARS-CoV-2 IgG Ab test was positive, indicating that longer duration
217 between pre-mortem testing and time of death may not yield positive post-mortem tests due to a
218 reduction in viral load in the upper respiratory tract. All ocular tissue swabs were negative for viral
219 RNA.

220 **Case #5:** A Caucasian female in her 70s was admitted to the hospital with symptoms of respiratory
221 distress. The patient tested positive for COVID-19 by PCR assay on the same day and 23 days
222 after hospital admission. The patient passed away three days after final positive COVID-19
223 test. The post-mortem NP swab test was positive for SARS-CoV-2 RNA, and the anti-SARS-CoV-
224 2 IgG Ab test was positive as well, indicating prolonged active infection with seroconversion.
225 However, to our surprise, all ocular tissue swabs were negative.

226 **Case #6:** A Hispanic male in his late 60s was admitted to the hospital after being found
227 unresponsive. The patient was deemed positive for COVID-19 via PCR assay on the next day after

228 hospital admission. The patient passed away 10 days after testing positive for COVID-19. The
229 post-mortem NP swab test for the presence of SARS-CoV-2 RNA, anti-SARS-CoV-2 IgG, and
230 IgM Abs were positives. Among the ocular tissue swabs, the left conjunctiva tested positive for
231 SARS-CoV-2 RNA. All other ocular tissue swabs were negative.

232 **Case #7:** A Caucasian female in her late 50s was admitted to the hospital with a fever of 102.8°F,
233 progressive weakness over the past few days, and a dry cough for the past two weeks. On the same
234 day, the patient tested positive for COVID-19 via PCR assay and tested positive again on 12th day
235 after hospital admission. The patient subsequently passed away three days after final positive
236 COVID-19 test. This was the first case we assessed in which ocular tissues tested positive for
237 SARS-CoV-2 RNA while the post-mortem NP swab was negative for viral RNA. Among the
238 ocular tissue swabs, the right posterior cornea and left vitreous tested positive. All other ocular
239 tissue swabs were negative. This donor also had positive IgG antibodies against SARS-CoV-2.

240 **Case #8:** A Hispanic female in her early 90s was admitted to the hospital and tested positive for
241 COVID-19 by PCR assay on the same day. The patient passed away 11 days after testing positive
242 for COVID-19. Similar to Case #4, the post-mortem NP swab test was negative but the anti-SARS-
243 CoV-2 IgG Ab test was positive, probably due to a relatively longer duration between pre-mortem
244 testing and time of death. Interestingly, among the ocular tissue swabs, the right posterior cornea
245 tested positive for SARS-CoV-2. All other ocular tissue swabs were negative.

246 **Case #9:** An African American male in his late 40s was admitted to the hospital for difficulty in
247 breathing, productive cough, abdominal distension, and worsening lower extremity edema. The
248 patient tested positive for COVID-19 by PCR assay on the same day. He passed away next day
249 after hospital admission. Post-mortem NP swab testing for the presence of SARS-CoV-2 RNA
250 was positive but the anti-SARS-CoV2-IgG Ab test was negative, indicating early-stage infection

251 with incomplete seroconversion. This donor had positive swabs from both conjunctivae, right
252 anterior cornea, right posterior cornea, and both vitreous. Left anterior and posterior corneal swabs
253 tested negative.

254 **Case #10:** A Hispanic male in his 40s was admitted to the hospital for flu-like symptoms that
255 developed six days before admission. He tested positive for SARS-CoV-2 via PCR tests that were
256 performed on the day of admission and 42 days after admission. The patient passed away 3 days
257 after final positive COVID-19 test. Similar to Case #3, the post-mortem NP swab test was positive
258 for SARS-CoV-2 RNA and anti-SARS-CoV-2-IgG Ab test was positive, indicating prolonged
259 active infection along with seroconversion. However, all ocular tissue swabs were negative
260 indicating that SARS-CoV-2 RNA might be absent from ocular tissues despite positive post-
261 mortem NP swab if the patient had COVID-19 for a longer duration.

262 In summary, of the 10 donors, we determined six donors had positive post-mortem NP
263 swabs and 8 donors had positive anti-SARS-CoV-2-IgG antibodies. Two donors (cases 2 and 9)
264 with negative IgG exhibited positive NP swabs, which might indicate an early stage of infection
265 without seroconversion. Nonetheless, all 10 donors had either a positive post-mortem NP swab or
266 a positive IgG, validating pre-mortem testing, and diagnosis of COVID-19. Across all 20 eyes:
267 Three conjunctival, one anterior corneal, five posterior corneal, and three vitreous swabs tested
268 positive for SARS-CoV-2 RNA, exhibiting a positivity rate of 15% for conjunctiva, 5% for
269 anterior corneal surface, 25% for posterior corneal surface, and 15% for vitreous (Table 3).

270 **Immunohistochemical Validation**

271 Right corneal tissue that were procured without any PVP-I disinfection and showed overall
272 stronger positivity (lower CT value) for SARS-CoV-2 was immunostained to detect viral antigens.
273 Our IHC data showed that coinciding with positive viral RNA, SARS CoV-2 Envelope protein

274 (Fig. 2), and Spike protein (Fig. 3) were detected in the COVID-19 patient's right corneas (Cases
275 7-9). The positive staining was primarily observed in epithelial layer of the cornea. In contrast, no
276 positivity for spike protein was visualized in COVID-19 negative patient corneas (healthy control).
277 Non-specific antibody binding was ruled out by staining sections with a secondary antibody only
278 as control. Also, the specificity of antibodies was validated by infecting cells with live SARS-
279 CoV-2 and staining them for spike protein (data not shown).

280

281 **Discussion:**

282 Cornea transplant is usually a safe ophthalmic procedure with little morbidity. However,
283 there is always a potential risk for transmission of infectious agents, especially viruses, from
284 donors to recipients or causing graft complications [16]. Eye banks follow elaborate procedures to
285 mitigate this risk through extensive donor screening including testing for the presence of microbial
286 pathogens (REF). Because of increased mortality due to COVID-19 and high transmissibility of
287 the SARS-CoV-2 virus, we investigated its prevalence in ocular tissues, which is currently
288 unknown. In this study, for the first time, we report the presence of not only SARS-CoV-2 RNA
289 but also its envelope and spike proteins in ocular tissues of donors who had COVID-19 at the time
290 of death. SARS-CoV-2 RNA was also detected in 13% (17 out of 132) corneal and scleral tissues
291 recovered from 33 asymptomatic positive carriers or symptomatic negative donors. Overall, our
292 findings underscore the criticality of post-mortem PCR testing, PVP-I disinfection protocol and
293 donor screening guidelines in eye banking to eliminate the possibility of handling tissues with
294 SARS-CoV-2 RNA particles. It is important to note that, while our data showed the presences of
295 viral RNA and antigens in the corneas of COVID-19 patients, further studies are necessary to

296 explore the possibility of transmission via ocular tissues and concentration dependent anti-virulent
297 activity of PVP-I.

298 In the context of the route of administration, it has been proposed that the virus travels via
299 direct airborne transmission since the entire ocular surface including the anterior cornea, tear film
300 and conjunctiva communicates with air, similar to the nasal mucosa. Another proposed path of
301 infiltration is the nasolacrimal route, facilitating the transport of viral particles from the respiratory
302 tract to the ocular surface or vice versa [17]. These potential routes of infiltration may justify
303 reports suggesting that SARS-CoV-2 causes conjunctivitis in COVID-19 positive patients [4-6, 9,
304 10, 18]. Incidences of conjunctivitis in these reports are mainly in the range of 0.8-6% but they
305 can be as high as 32% and 66% (for a detailed review, please refer to [19]).

306 Although the primary route of SARS-CoV-2 infiltration could be via respiratory droplets,
307 a potential non-respiratory route of transmission cannot be ignored. To our surprise, we observed
308 a higher prevalence of SARS-CoV-2 RNA in the posterior corneal (endothelial) surface than from
309 any other ocular surface swabs (Table 3). This finding and current literature highlighting the
310 prevalence of SARS-CoV-2 in extra-respiratory routes such as blood [14, 15] led us to hypothesize
311 that vascular endothelium-enriched ocular tissues could be the source of posterior corneal
312 infectivity. To test this hypothesis, we analyzed iris samples from COVID-19 donors for the
313 presence of SARS-CoV-2 RNA. Surprisingly, none of the iris samples showed detectable levels
314 of SARS-CoV-2 RNA via PCR test (data not shown). We also detected SARS-CoV-2 RNA in two
315 of 20 vitreous swabs. Similarly, a recent study demonstrated 21% (3/14) prevalence rate of SARS-
316 CoV-2 RNA in the retinal biopsies of deceased COVID-19 patients [11]. Hence, the possibility of
317 infiltration via retinal vasculature could not be eliminated. Our findings of a higher prevalence of
318 SARS-CoV-2 RNA in the posterior corneal (endothelial) surface than on any other ocular surface

319 remain intriguing, and further studies are required to decipher the detailed mechanism. As
320 postulated by Ang and colleagues [20], a contributing factor for this finding could be higher
321 antimicrobial activity on the ocular surface. Tear film contains antimicrobial protein lactoferrin,
322 which has been postulated to prevent bindings of SARS-CoV-2 to the ACE2 receptors on anterior
323 corneal and conjunctival surfaces.

324 An initial study goal was to detect the effectiveness of PVP-I in inactivating the SARS-
325 CoV-2. Therefore, we recovered right eyes without PVP-I exposure, and left eyes were recovered
326 following EBAA-recommended double PVP-I soak procedure. We are unable to make conclusive
327 remarks about the effectiveness of PVP-I, due to the small sample size (10 cases) of this study.
328 However, we note that all of the anterior corneal surface swabs from left eyes (PVP-I treated) were
329 negative for SARS-CoV-2 RNA, whereas one out of 10 right eye swabs was positive. Although
330 many studies have demonstrated the virucidal activity of PVP-I against other similar viruses such
331 as MERS-CoV and SARS-CoV [21-24], there is no literature explaining the mechanism of action
332 of PVP-I to inactivate SARS-CoV-2. The possibility of PVP-I mediated SARS-CoV-2 RNA
333 degradation could not be eliminated. There is still a possibility that the PCR testing amplified non-
334 intact SARS-CoV-2 RNA. As we learn more about the genomic sequence of the virus, more efforts
335 should be made toward designing better PCR primers that are indicative of RNA cleavage patterns
336 and resistant to mutational changes in the SARS-CoV-2. Such specific primers will help us classify
337 ineffective positive PCR testing from a non-infective positive PCR test.

338 Respiratory viruses, including influenza virus have shown tropism towards the eye [25, 26]
339 and have been reported to infect and replicate at the ocular surface [27]. To our knowledge, our
340 study is the first, to show SARS-CoV-2 antigens in ocular tissue of COVID-19 patients that were
341 procured without PVP-I disinfection treatment, supporting the idea that SARS-CoV-2 could infect

342 corneal epithelial cells. We previously showed that corneal epithelia cells elicit innate responses
343 upon viral stimuli such as ZIKV [28] or PolyI:C, a viral mimic of dsRNA [29]. However, further
344 studies are necessary to understand if potential transmission of SARS-CoV-2 through the ocular
345 surface is possible.

346 In summary, we report the presence of SARS-CoV-2 RNA and proteins in the ocular
347 tissues of donors who had COVID-19 at the time of death or had related signs and symptoms. It is
348 unclear whether the presence of SARS-CoV-2 RNA and proteins is due to primary ocular surface
349 infection or due to retrograde transport of viral particles from the upper respiratory tract via the
350 nasolacrimal duct. It is also unclear whether SARS-CoV-2 can replicate in corneal and/or
351 conjunctival cells and what changes occur in infected ocular surface cells. Further studies
352 including live virus culture, the infectivity of ocular surface cells, and elucidation of biomarkers
353 for viral infections such as induction of inflammatory and antiviral responses are needed to
354 establish the link that the eye is a portal for entry and transmission of SARS-CoV-2. Nonetheless,
355 our study strongly recommends simultaneous implementation of post-mortem PCR testing, PVP-
356 I disinfection protocol and thorough donor screening according to EBAA and CDC guidelines to
357 mitigate the potential risk of transplanting a tissue with SARS-CoV-2 particles.

358

359 **Acknowledgments:**

360 This work was supported by research grants from the Eye Bank Association of America (SIM,
361 OBS, MST, PAM, AK), National Eye Institute (AK – EY027381, EY026964), and National
362 Institute of Allergy and Infectious Diseases (AK – AI135583, AI140033). We also acknowledge
363 our organ procurement organization (OPO) partners Gift of Life Michigan and New Jersey Sharing
364 Network for referring COVID-19 donors for this study and Eversight’s Donation Support Center

365 (DSC) for screening these donors. We thank Miracles in Sight (Winston-Salem, NC) and
366 Transplant Services Center-UT Southwestern Medical Center (Dallas, TX) for contributing
367 donated tissues to this study. Last and importantly, we thank the donors and their families whose
368 gifts of donated eye tissue and consent for research is helping us advance the science and
369 understanding of COVID-19 to benefit all those in need of safe transplantation and the gift of sight.

370 **References:**

- 371 1. Lescure, F.X., et al., *Clinical and virological data of the first cases of COVID-19 in Europe: a case*
372 *series*. Lancet Infect Dis, 2020.
- 373 2. Zou, L., et al., *SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients*. N Engl J
374 Med, 2020. **382**(12): p. 1177-1179.
- 375 3. Seah, I. and R. Agrawal, *Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review*
376 *of Coronaviruses and Ocular Implications in Humans and Animals*. Ocul Immunol Inflamm, 2020.
377 **28**(3): p. 391-395.
- 378 4. Xia, J., et al., *Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-*
379 *CoV-2 infection*. J Med Virol, 2020.
- 380 5. Wu, P., et al., *Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-*
381 *19) in Hubei Province, China*. JAMA Ophthalmol, 2020.
- 382 6. Guan, W.J., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China*. N Engl J Med, 2020.
- 383 7. Colavita, F., et al., *SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy*
384 *With Prolonged Viral RNA Detection*. Ann Intern Med, 2020.
- 385 8. Chen, L., et al., *Ocular manifestations of a hospitalised patient with confirmed 2019 novel*
386 *coronavirus disease*. Br J Ophthalmol, 2020.
- 387 9. Seah, I.Y.J., et al., *Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019*
388 *(COVID-19) Patients*. Ophthalmology, 2020. **127**(7): p. 977-979.
- 389 10. Zhou, Y., et al., *Ocular Findings and Proportion with Conjunctival SARS-COV-2 in COVID-19*
390 *Patients*. Ophthalmology, 2020. **127**(7): p. 982-983.
- 391 11. Casagrande, M., et al., *Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19*
392 *Patients*. Ocul Immunol Inflamm, 2020. **28**(5): p. 721-725.
- 393 12. Zhou, L., et al., *ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting*
394 *susceptibility to SARS-CoV-2 infection*. Ocul Surf, 2020.
- 395 13. Roehrich, H., C. Yuan, and J.H. Hou, *Immunohistochemical study of SARS-CoV-2 viral entry factors*
396 *in the cornea and ocular surface*. Cornea, 2020.
- 397 14. Le, C., et al., *Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations*.
398 Emerging Infectious Disease journal, 2020. **26**(7).
- 399 15. Wang, W., et al., *Detection of SARS-CoV-2 in Different Types of Clinical Specimens*. JAMA, 2020.
- 400 16. Jin, S.X. and V. Juthani, *Acute Corneal Endothelial Graft Rejection with Coinciding COVID-19*
401 *Infection*. Cornea, 2020.
- 402 17. Collin, J., et al., *Co-expression of SARS-CoV-2 entry genes in the superficial adult human*
403 *conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular*
404 *surface*. Ocul Surf, 2020.

- 405 18. Zhang, X., et al., *The evidence of SARS-CoV-2 infection on ocular surface*. Ocul Surf, 2020. **18**(3): p.
406 360-362.
- 407 19. Ballouz, D. and S.I. Mian, *Eye banking in the coronavirus disease 2019 era*. Curr Opin Ophthalmol,
408 2020. **31**(5): p. 389-395.
- 409 20. Ang, M., et al., *Corneal transplantation in the aftermath of the COVID-19 pandemic: an*
410 *international perspective*. Br J Ophthalmol, 2020.
- 411 21. Eggers, M., et al., *In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine*
412 *Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens*. Infect Dis Ther, 2018. **7**(2): p.
413 249-259.
- 414 22. Eggers, M., M. Eickmann, and J. Zorn, *Rapid and Effective Virucidal Activity of Povidone-Iodine*
415 *Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified*
416 *Vaccinia Virus Ankara (MVA)*. Infect Dis Ther, 2015. **4**(4): p. 491-501.
- 417 23. Kampf, G., et al., *Persistence of coronaviruses on inanimate surfaces and their inactivation with*
418 *biocidal agents*. J Hosp Infect, 2020. **104**(3): p. 246-251.
- 419 24. Kariwa, H., N. Fujii, and I. Takashima, *Inactivation of SARS coronavirus by means of povidone-*
420 *iodine, physical conditions and chemical reagents*. Dermatology, 2006. **212 Suppl 1**: p. 119-23.
- 421 25. Belser, J.A., P.A. Rota, and T.M. Tumpey, *Ocular tropism of respiratory viruses*. Microbiol Mol Biol
422 Rev, 2013. **77**(1): p. 144-56.
- 423 26. Belser, J.A., et al., *The eyes have it: influenza virus infection beyond the respiratory tract*. The
424 Lancet. Infectious diseases, 2018. **18**(7): p. e220-e227.
- 425 27. Creager, H.M., et al., *Infection and Replication of Influenza Virus at the Ocular Surface*. Journal of
426 virology, 2018. **92**(7): p. e02192-17.
- 427 28. Singh, P.K., et al., *Interferon-stimulated gene 15 (ISG15) restricts Zika virus replication in primary*
428 *human corneal epithelial cells*. The Ocular Surface, 2019. **17**(3): p. 551-559.
- 429 29. Kumar, A., J. Zhang, and F.S. Yu, *Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in*
430 *human corneal epithelial cells*. Immunology, 2006. **117**(1): p. 11-21.

431

432

433

434

435

436

437

438

439

440

441 **Figure Legends**

442 **Figure 1: Simplified schematic representation of the procedures used for detection of SARS-**
443 **CoV-2 RNA and viral antigen in various ocular tissues.** Post-mortem blood and
444 nasopharyngeal (NP) swabs were used to confirm COVID-19 followed by collection of
445 conjunctival swab, anterior and posterior corneal swab, vitreous, and iris for RT-PCR detection of
446 SARS-CoV-2 RNA. Fixed corneal tissues from OD (right) eyes that were procured without any
447 PVP-I disinfection treatment were used for immunohistochemistry (IHC) detection of viral
448 antigens.

449 **Figure 2: SARS-CoV-2 Envelope (E) protein was detected in the cornea of the COVID-19**
450 **donors that were procured without any PVP-I disinfection treatment.** OD (right) cornea from
451 healthy and COVID-19 donors were fixed in formaldehyde and 10 μ m thin sections were stained
452 for IHC using antibody against SARS-CoV-2 Envelope (E) protein (red color) while DAPI was
453 used for nuclear staining (blue color). The image was captured at different magnifications (10X,
454 20X, and 60X) to visualize cellular location of the viral proteins. The region of interest has been
455 highlighted using a yellow box and white arrows. **E**, corneal epithelium; **S**, corneal stroma.
456 Sections stained with secondary antibody (anti-mouse Alexa Fluor 594) was used to assess the
457 antibody specificity.

458 **Figure 3: SARS-CoV-2 Spike (S) protein was detected in the corneal epithelium of the**
459 **COVID-19 donors that were procured without any PVP-I disinfection treatment.** OD (right)
460 cornea from healthy and COVID-19 donors were fixed in formaldehyde and 10 μ m thin sections
461 were stained for IHC using antibody against SARS-CoV-2 Spike (S) protein (red color) while
462 DAPI was used for nuclear staining (blue color). The image was captured at different
463 magnifications (10X, 20X, and 60X) to visualize cellular location of the viral proteins. The region
464 of interest has been highlighted using a yellow box and white arrows. **E**, corneal epithelium; **S**,
465 corneal stroma. Sections stained with secondary antibody (anti-mouse Alexa Fluor 594) was used
466 to assess the antibody specificity.

467

Table 1: SARS-CoV-2 PCR results for surgically ruled-out tissues

Groups	COVID-19 Positive (Group 1)		Signs and Symptoms of COVID-19 (Group 2)		Close Contact With COVID-19 Patient (Group 3)	
	Sclera	Cornea	Sclera	Cornea	Sclera	Cornea
Number of Cases	18		13		2	
Median Age (Range)	61 (17-72)		59 (26-75)		63 (62-63)	
Tissue Type	Sclera	Cornea	Sclera	Cornea	Sclera	Cornea
Number of Tissues	36	36	26	26	4	4
RNA Concentration (Ng/μl)	520 ± 61	537 ± 66	539 ± 50	486 ± 41	591 ± 65	522 ± 69
Number of Positive Tissues	6	4	3	4	0	0
*Ct (Mean ± SD)	33 ± 2	32 ± 2	35 ± 1	29 ± 7		
Positivity Rate	17%	11%	12%	15%	0%	0%

*Ct refers to number of PCR cycles


Table 2: Donor demographics and pre-mortem testing results

Case #	Gender	Race	Pre-Mortem COVID-19 Test Result	Pre-Mortem Testing to Death Interval (days)
1	Male	Caucasian	Positive	6
2	Female	Caucasian	Positive	9
3	Male	Caucasian	Positive	7
4	Male	South Asian	Positive	15
5	Female	Caucasian	Positive	3
6	Male	Hispanic	Positive	10
7	Female	Caucasian	Positive	3
8	Female	Hispanic	Positive	11
9	Male	Black	Positive	1
10	Male	Hispanic	Positive	3

Table 3: Post-mortem SARS-CoV-2 testing results

Case #	NP-PCR	IgG	IgM	Eye	Conjunctiva	Anterior Cornea	Posterior Cornea	Vitreous
Case #1	Positive	Positive	-ve	Right	-ve	-ve	Positive	-ve
				Left	-ve	-ve	-ve	-ve
Case #2	Positive	-ve	-ve	Right	-ve	-ve	-ve	-ve
				Left	-ve	-ve	Positive	-ve
Case #3	-ve	Positive	-ve	Right	-ve	-ve	-ve	-ve
				Left	-ve	-ve	-ve	-ve
Case #4	-ve	Positive	-ve	Right	-ve	-ve	-ve	-ve
				Left	-ve	-ve	-ve	-ve
Case #5	Positive	Positive	-ve	Right	-ve	-ve	-ve	-ve
				Left	-ve	-ve	-ve	-ve
Case #6	Positive	Positive	Positive	Right	-ve	-ve	-ve	-ve
				Left	Positive	-ve	-ve	-ve
Case #7	-ve	Positive	-ve	Right	-ve	-ve	Positive	-ve
				Left	-ve	-ve	-ve	Positive
Case #8	-ve	Positive	-ve	Right	-ve	-ve	Positive	-ve
				Left	-ve	-ve	-ve	-ve
Case #9	Positive	-ve	-ve	Right	Positive	Positive	Positive	Positive
				Left	Positive	-ve	-ve	Positive
Case #10	Positive	Positive	-ve	Right	-ve	-ve	-ve	-ve
				Left	-ve	-ve	-ve	-ve
Positivity Rate	60%	80%	10%		15%	5%	25%	15%

Figure 1






Figure 3